In May 2009, a new clinical practice guideline for gastric cancer was released in the Netherlands. To determine the impact of this guideline, we evaluated trends in patterns of care, thereby focusing on the use of perioperative chemotherapy, the adequacy of lymphadenectomy and the proportion of non-curative resections. For our evaluation, we retrospectively collected information from the Netherlands Cancer Registry on 2,511 patients diagnosed with primary adenocarcinoma of the stomach during the period July 2008-June 2010, excluding tumors of the cardia. After comparing clinical management for patients diagnosed from July 2008 to June 2009 with that for patients diagnosed from July 2009 to June 2010, we conclude that our indicators for guideline adherence did not show major change, except for the proportion of patients that received an adequate lymphadenectomy (examination of ≥10 lymph nodes), which increased from 49% to 58% (p = 0.005), this increase being more pronounced for high-volume hospitals (p = 0.006). Preoperative chemotherapy was given in 45% of patients and 25% of resections was non-curative. For the total study population, the resection rate was 41% and 30-day mortality was 5.7%. However, this measure may underestimate the real operative risk for gastric cancer patients given supplementary information on postdischarge death and prolonged hospital stay.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27718DOI Listing

Publication Analysis

Top Keywords

gastric cancer
12
patients diagnosed
12
diagnosed july
8
patients
6
adherence national
4
national guidelines
4
guidelines gastric
4
cancer
4
cancer netherlands
4
netherlands retrospective
4

Similar Publications

C118P Suppresses Gastric Cancer Growth via Promoting Autophagy-Lysosomal Degradation of RAB1A.

Pharmaceutics

December 2024

New Drug Screening and Pharmacodynamics Evaluation Center, National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing 210009, China.

: Gastric cancer (GC) is the leading cause of cancer-related deaths worldwide. C118P, a microtubule inhibitor with anti-angiogenic and vascular-disrupting activities, was proven to be cytotoxic to various cancer cell lines. This study aimed to explore the anti-tumor effect of C118P against gastric cancer and identify its potential target.

View Article and Find Full Text PDF

Background/objectives: Gastric cancer is one of the leading malignancies worldwide. B vitamins play important roles in DNA synthesis and methylation because they are considered co-enzymes in one-carbon metabolism. There is inconclusive evidence regarding the associations between dietary vitamins B, B, and B with the risk of gastric cancer in different epidemiologic studies.

View Article and Find Full Text PDF

The WHO has classified Helicobacter pylori as a group 1 carcinogen for stomach cancer since early 1994. However, despite the high prevalence of Helicobacter pylori infection, only about 3% of infected people eventually develop gastric cancer.Biomolecular detections of Helicobacter pylori(HP) were compared using specially modified sensors and fluorine immobilized on a carbon nanotube (HFCNT) electrode, which yielded sensitive results.

View Article and Find Full Text PDF

Inhibition, Gastritis Attenuation, and Gut Microbiota Protection in C57BL/6 Mice by NCUH062003.

Microorganisms

December 2024

State Key Laboratory of Food Science and Resources, Nanchang University, No. 235 Nanjing East Road, Nanchang 330047, China.

(), one of the most prevalent pathogenic bacteria worldwide, is the leading cause of gastritis, gastric intestinal metaplasia, and gastric cancer. Antibiotics, the conventional treatment for eliminating , often lead to severe bacterial resistance, gut dysbiosis, and hepatic insufficiency and fail to address the inflammatory response or gastric mucosal damage caused by infection. In this study, based on 10-week animal experiments, two models of NCUH062003 for the prophylaxis and therapy of infection in C57BL/6 mice were established; a comprehensive comparative analysis was performed to investigate the anti- effect of probiotics, the reduction in inflammation, and repair of gastric mucosal damage.

View Article and Find Full Text PDF

Attenuates 5-Fluorouracil-Induced Intestinal Mucositis in Mice.

Pharmaceuticals (Basel)

December 2024

Laboratory of Gastrointestinal Physio-Pharmacology (LEFFAG), Federal University of Ceará, Coronel Nunes de Melo Street, 1315 Rodolfo Teófilo, Fortaleza 60416-030, CE, Brazil.

5-Fluorouracil (5-FU) is an antimetabolite widely prescribed in cancer treatments, but its use in highly proliferative tissues can cause significant problems such as mucositis. is a probiotic commonly used for protection against acute diarrhea, gastrointestinal dysbiosis and inflammatory bowel diseases. We investigated the effect of on 5-FU intestinal mucositis in mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!